Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01813773 · ClinicalTrials.gov registry record · Phase 2
Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study
A Phase 2 study, sponsored by Ophthalmic Consultants of Long Island.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01813773 is a Phase 2 study that has completed, run by Ophthalmic Consultants of Long Island. The registered enrollment target is 20 participants.
The verdict
NCT01813773, a Phase 2 study, has completed, sponsored by Ophthalmic Consultants of Long Island.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
To assess the safety of intravitreal aflibercept injection in the treatment of proliferative diabetic retinopathy (PDR) by evaluating the incidence and severity of adverse events.
Interventions
- DRUG Intravitreal Aflibercept Injection (IAI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01813773
The ClinicalTrials.gov registry entry for NCT01813773 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthalmic Consultants of Long Island, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal Aflibercept Injection (IAI) is the first listed.
NCT01813773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01813773 about?
NCT01813773 is a clinical study titled "Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study". To assess the safety of intravitreal aflibercept injection in the treatment of proliferative diabetic retinopathy (PDR) by evaluating the incidence and severity of adverse events.
What is the current status of trial NCT01813773?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01813773?
The interventions under investigation include: Intravitreal Aflibercept Injection (IAI) (DRUG).
Who is sponsoring clinical trial NCT01813773?
This trial is sponsored by Ophthalmic Consultants of Long Island, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.